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Abstract
Introduction. Sunitinib is an oral inhibitor of vascular endothelial growth factor that is used to treat a variety of 
cancer. There are limited data regarding the effect of sunitinib on diabetes. In the liver, Notch signaling plays 
an important role in liver tissue development and homeostasis and its dysfunction is associated with liver pathol-
ogies. The aim of the present study is to investigate the effects of sunitinib on streptozotocin (STZ)-induced 
diabetic liver in mice models. 
Material and methods. An experimental diabetes mellitus (DM) model was created in 28 male CD-1 mice. 
Twenty-eight male CD-1 mice divided in four groups (n = 7 each) were used; control mice (C), control mice 
treated with sunitinib (C + S), diabetic mice (DM), and diabetic mice treated with sunitinib (DM + S) for four 
weeks. The histopathological changes in the liver were examined by histochemistry and immunohistochemistry. 
Immunoreactivity of Notch1, Jagged1, DLL-1 and VEGF were evaluated in control and diabetic mice after 
sunitinib treatment.
Results. The significant morphological changes in the liver were mostly seen in hepatocytes that were hyper-
trophied in the DM mice, with an increased amount of eosinophilic granules; moreover, some hepatocytes 
contained empty vacuole-like structures. The livers of the DM mice revealed increased deposition of collagen 
fibers. After sunitinib treatment the hepatocytes and hepatic lobules had almost similar morphology to control 
mice. The immunoreactivities of Notch1, Jagged1, DLL-1 and VEGF in hepatocytes were significantly lower in 
the DM group when compared with the C, DM + S and C + S group treated with sunitinib. 
Conclusions. These results suggest that sunitinib effectively protects the liver from diabetes-induced damage 
through the inhibition of the Notch pathway. (Folia Histochemica et Cytobiologica 2017, Vol. 55, No. 3, 140–148)
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Introduction
Diabetes mellitus (DM) is one of the most prevalent 
endocrine metabolic disorders resulting from a defect 
in insulin secretion which results in hyperglycemia 
and abnormalities in the metabolism of proteins, 
fats and carbohydrates. Worldwide, the incidence 
of DM has increased strikingly in recent decades. 
The two main types of diabetes are type 1 diabetes 
(T1D) and type 2 diabetes (T2D). T1D, also termed 
juvenile-onset or insulin-dependent diabetes, is 
a global health problem and its incidence is rapidly 
increasing [1]. T1D is a chronic autoimmune disease 
and a metabolic disorder which is characterized by 
selective destruction of insulin-producing b-cells in 
the islets of Langerhans, resulting in insulin defi-
ciency and hyperglycemia [2]. DM-related long-term 
complications that involve blood vessels, kidney, eyes, 
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and peripheral nervous system are the leading caus-
es of morbidity and mortality in patients with DM, 
but only limited data are available on the possible 
association between diabetic complications and liver 
structure and function [3]. T1D patients frequently 
experience ketosis (hyperketonemia) because in 
a state of insulin deficiency, energy is derived mainly 
from fat stores [4]. Experimental T1D can be induced 
in animals by the administration of chemicals such as 
streptozotocin (STZ) and alloxan. STZ is widely used 
to induce insulin-dependent DM because of its toxic 
effects on pancreatic islets’ b-cells [5]. 
The liver plays a central and crucial role in glucose 
homeostasis by maintaining a balance between uptake 
and storage of glucose as glycogen. This central role 
of the liver in the regulation of carbohydrate home-
ostasis is important to understand many biochemical 
alterations that occur in the diabetic liver. Although 
the prevalence of liver diseases among diabetics has 
been estimated to be between 17% and 100% [6], 
their pathomechanisms have not been well elucidat-
ed. In DM the failure of hepatocytes to respond to 
insulin contributes to uncontrolled gluconeogenesis, 
glycogenolysis and lipogenesis, which lead to such 
complications as steatohepatitis and hepatocellular 
carcinoma [7]. Cancer is more frequent among dia-
betic patients compared to non-diabetics. The studies 
on the association between DM and hepatocellular 
carcinoma (HCC) have shown that relative risks 
of HCC among people with diabetes are especially 
high soon after the diagnosis of diabetes had been 
established [8, 9].
In recent years, structural and functional studies 
revealed that tyrosine kinases (TKs) act as the essen-
tial components in many signal transduction pathways 
and therefore become potential therapeutic targets. 
The tyrosine-kinase inhibitors (TKIs), small molecular 
and hydrophobic compounds, inhibit activity of TKs. 
TKIs have proven to be successful in the treatment of 
a wide variety of malignant diseases. Some inhibitors 
of tyrosine kinase, such as imatinib, erlotinib and 
sunitinib, have antihyperglycemic effects. It has been 
recently found that small-molecule protein tyrosine 
kinase inhibitors (PTKIs) can prevent or even reverse 
the development of diabetes in an established animal 
model [10, 11]. Little et al. [12] suggest that TKIs 
have anti-diabetic effects in both T1D and T2D, and 
that this could be mediated by both improved b-cell 
survival and decreased insulin resistance in the main 
target tissues [13]. Sunitinib, chemically known as 
SU-11248, is an oral oxindole multi-targeted receptor 
tyrosine kinase (RTK) inhibitor that exhibits potent 
antiangiogenic and antitumor activities. Sunitinib 
has been identified as a potent inhibitor of vascular 
endothelial growth factor receptors (VEGFR type 1 
and 2), platelet-derived growth factor receptors 
(PDGFR-a and PDGFR-b), stem cell factor receptor 
(KIT) in both biochemical and cellular assays [14, 15]. 
Sunitinib has been recently shown to have potential 
therapeutic utility for the treatment of patients with 
DM [16, 17].
Notch signaling pathway is a highly conserved 
cell signaling system present in most multicellular 
organisms. The Notch pathway regulates cell prolifer-
ation, differentiation, cell fate specification and organ 
development during embryonic and adult life. In the 
liver, Notch signaling has recently been recognized 
as a key player in glycogenolysis and gluconeogenesis 
processes, with abnormal activation of Notch signaling 
in hepatocytes leading to hyperglycemia and fatty liver 
disease [18]. Notch itself is a transmembrane receptor 
that transduces short-range signals by interacting with 
cell surface ligands such as jagged and delta that are 
associated with the surface of neighboring cells. Upon 
activation by ligand binding, Notch is proteolytically 
cleaved within its transmembrane domain by prese-
nilin-1/c secretase resulting in the release of a Notch 
intracellular domain (NICD) which translocates to 
the nucleus where it activates the transcription of 
downstream target genes. 
Vascular endothelial growth factor (VEGF) plays 
a key role in vasculogenesis and angiogenesis by stim-
ulating endothelial cell mitosis and migration in many 
tissues. VEGF appears to play a central role in the 
microvascular complications in T1D and T2D [19]. 
Interaction between VEGF and Notch signaling has 
been reported in diabetes [20]. 
Several studies showed that sunitinib was used for 
the treatment of a wide range of diseases, including 
infectious diseases, alongside autoimmune and ma-
lignant disorders. The use of sunitinib is becoming 
more common. Therefore, it seems to be important 
to know whether sunitinib has a therapeutic poten-
tial in diabetes. The aim of the present study was to 
investigate the effects of sunitinib in a mouse model 
of streptozotocin-induced diabetes by the use of his-
tochemistry and immunohistochemistry.
Material and methods
Animals. In this study, 28 male CD-1 mice aged 8 weeks 
and weighing 20–30 g were selected. Animals were fed ad 
libitum and housed under standard laboratory conditions 
(12:12 h light:dark cycle, 24°C room temperature, ~60% 
humidity). The experimental procedures were approved by 
the Committee for Animal Research of the Ege University, 
Turkey. All animal studies strictly conformed to the animal 
experiment guidelines of the Committee for Human Care. 
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Diabetes was induced in 14 mice by intraperitoneal (ip) 
injection of single dose of 60 mg/kg STZ [2-deoxy-2-(3-(me-
thyl-3-nitrosoureido)-D-glucopyranose] (Sigma-Aldrich, 
St Louis, MO, USA) (STZ was dissolved in 0.9% NaCl, 
adjusted to pH 4.0 with 0.2 M sodium citrate buffer). In 
the control group the level of blood glucose was below 120 
mg/dL (n = 7). DM was verified after 48 h by evaluating 
blood glucose levels with the use of glucose oxidase reagent 
strips (Boehringer, Mannheim, Germany) from tail vein. 
The blood glucose levels were 250 mg/dL and higher in the 
diabetic mice. The 14 diabetic mice were randomly divided 
into 2 groups: DM group received 0.2 mL of 0.9% saline 
(n = 7), whereas diabetic mice treated with sunitin-
ib, designed as DM + S group (n = 7), received 
1.5 mg/kg/day sunitinib in 0.2 mL of 0.9% saline. Saline or 
sunitinib were administered to diabetic mice by ip injections 
for 4 weeks. Then, the animals were euthanized and the 
liver was removed for histopathological evaluation.
Histopathological examination. For histological studies, 
all animals were anesthetized with ip injection of ketamine 
(40 mg/kg) and xylazine (4 mg/kg) and perfused with 200 mL 
of 4% formaldehyde in 0.1 M phosphate-buffered saline 
(PBS). Formalin-fixed liver samples were processed into 
paraffin blocks, sectioned at 5 mm and stained with hema-
toxylin and eosin (H&E) and Masson’s trichrome method. 
All sections were photographed using an Olympus C-5050 
digital camera (Olympus Optical Co., Tokyo, Japan) mount-
ed on an Olympus BX51 microscope. 
Immunohistochemistry. 5 mm-thick sections were cut us-
ing semi-motorized rotary microtome (Leica MR 2145); 
they were then dewaxed and rehydrated through a graded 
ethanol series using routine protocols. Sections were then 
washed with distilled water and PBS for 10 min, then treat-
ed with 2% trypsin (Sigma-Aldrich) in 50 mM Tris buffer 
(pH 7.5), at 37°C for 15 min. Sections were delineated with 
a Dako pen (Dako, Glostrup, Denmark) and incubated in 
a solution of 3% H2O2 for 15 min to inhibit endogenous 
peroxidase activity. Next, the sections were incubated with 
primary antibodies directed against DLL1 (1:100; bs-7435R 
Bioss, Beijing, China), Notch1 (1:1000; bs-1196R Bioss), 
Jagged1 (1:100; bs-1448R, Bioss), VEGF (1:100; sc-7269, 
Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) 
all for 24 h at 4°C in a humid chamber. Sections were then 
incubated with biotinylated secondary antibody and then 
with streptavidin conjugated to horseradish peroxidase 
(both from Zymed Histostain-Plus Peroxidase kit, 85-9043, 
Zymed Laboratories, San Francisco, CA, USA) prepared 
according to manufacturer’s instruction for 30 min each. 
Finally, sections were incubated with 3’,3’-diaminobenzidine 
(DAB) (Dead End Colorimetric TUNEL system, Promega, 
Madison, WI, USA) prepared according to manufacturer’s 
instruction, for 5 min to reveal immune labeling. All dilu-
tions and thorough washes between stages were performed 
with PBS. Sections were counterstained with Mayer’s he-
matoxylin (Zymed Laboratories). After washing with tap 
water, sections were dehydrated through a graded ethanol 
series, cleared in xylene and mounted with Entellan (Merck, 
Darmstadt, Germany). Microphotographs were obtained us-
ing Olympus C-5050 digital camera mounted on an Olympus 
BX51 microscope. The number of positive cells was assessed 
systematically by scoring at least 100 cells per 10 view-fields 
of tissue sections at ×20 magnification independently by 
three histologists.
Semiquantitative assessment of the immunoreactivity of the 
studied proteins. VEGF, DLL-1, Jagged 1 and Notch-1 im-
munohistochemical semi-quantitation was determined using 
the modified H-score (Histoscore). H-score was calculated 
by a semi-quantitative assessment of both the intensity of 
staining (graded as: 0, non-staining; 1, weak; 2, median; 3, 
strong) and the percentage of positive cells. The range of 
possible scores was from 0 to 300. Expression level of each 
component was categorized as low or high according to the 
median value of the H-score.
Statistical analysis. Data analyses were performed by Sta-
tistical Package for Social Sciences software, version 15.0 
for Windows (SPSS, Chicago, IL, USA). The groups of 
parametric variables were compared by Student’s t-test and 
analysis of variance. The groups of nonparametric variables 
were compared by Mann-Whitney U test. Results were 
given as mean + SEM. The value of p < 0.05 was accepted 
as statistically significant and p < 0.001 was accepted as 
statistically highly significant.
Results
Blood glucose concentration
Higher blood glucose levels were found in all 
the diabetic mice compared to the control group. The 
increase in blood glucose was observed 48 h after 
the STZ injection and was maintained throughout the 
study period (Table 1).
Histopathological analysis of the liver  
of diabetic mice treated with sunitinib
Examination of H&E-stained sections of liver of 
control mice showed normal histological architecture 
and normal lobular pattern with a centrilobular vein 
and radiating irregular anastomosing plates of hepat-
ocytes with intervening sinusoids lined with sinusoidal 
endothelial cells (Suppl. Fig. 1C). The characteristic 
histological alteration in the liver of STZ-treated 
mice was hypertrophy of hepatocytes. Many hyper-
trophic hepatocytes showed dense cytoplasm with an 
increased amount of eosinophilic granules. In some 
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cases, the cytoplasm of hepatocytes contained empty 
vacuole-like spaces (Suppl. Fig. 1A). H&E-stained 
liver sections of the sunitinib treated mice showed 
that morphology of most of hepatic lobules was almost 
similar to that of the normal control group (Suppl. 
Fig. 1C). Also, H&E-stained sections of the liver of 
the normal non-diabetic mice treated for four weeks 
with sunitinib (C + S) were similar to the normal 
control group (Suppl. Fig. 1D). 
The Masson Trichrome histochemical staining of the 
liver was applied to assess the presence of fibrosis. 
The livers of control mice appeared normal without 
signs of fibrosis (Suppl. Fig. 2C). The livers of the 
DM group revealed increased deposition of collagen 
fibers (Suppl. Fig. 2A). The livers of diabetic mice 
treated with sunitinib (Suppl. Fig. 2B) and nondiabetic 
mice treated with sunitinib (Suppl. Fig. 2D) showed 
moderate deposition of collagen fibers. 
Immunohistochemical analysis
Notch1 immunoreactivity 
In liver sections of the diabetic mice, strong immunop-
ositive reactions (Fig. 1a) were detected for Notch1 
when compared with the control (Fig. 1c and Fig. 2) 
(p < 0.001). Notch1 immunoreactivity in the hepat-
ocytes was significantly lower in the sunitinib-treated 
mice compared with the diabetes group (p < 0.05) 
Table 1. Blood glucose concentration of control, STZ- and sunitinib-treated mice
Time/group Control mice Control + sunitinib Diabetic mice Diabetic + sunitinib
Beginning of the study 93.34 ± 5.1 92.80 ± 4.2 565.51 ± 25.2* 567.14 ± 23.9*
End of the study 95.10 ± 3.2 90.12 ± 4.4 546.10 ± 57.7* 538.41 ± 40.4*
p value for time parameter NS NS NS NS
Values are expressed in mg/dL as mean ± SEM. *Statistically significant differences as compared to the control group (p < 0.05). NS — not signi-
ficant (p > 0.05).
Figure 1. Notch 1, Jagged 1, DLL-1 and VEGF immunoreactivity in the liver of diabetic and control mice treated with 
sunitinib. Diabetic mice (DM): 1a, 1e, 1l, 1m; diabetic mice treated with sunitinib (DM + S): 1b, 1f, 1i, 1n; control mice 
(C group): 1c, 1g, 1j, 1o; control mice treated with sunitinib (C + S): 1d,1h, 1k, 1ö.The immunohistochemical staining was 
performed as described in Material and methods. Scale bar: 50 mm. 
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(Fig. 1b and Fig. 2). There was no difference between the 
DM + S group and the C + S group (Fig. 1d and Fig. 2). 
Jagged1 immunoreactivity 
Jagged1 immunostaining was weak in the livers of 
control mice (Fig. 1g). In the DM group, Jagged1 
immunoreactivity was strong in the liver (Fig. 1e) 
when compared to the control group (p < 0.001) 
(Fig. 2). In the livers of sunitinib-treated diabetic 
mice the immunoreactivity of Jagged1 (Fig. 1f) was 
significantly lower than in the DM group. In C + S 
group (Fig. 1h), Jagged1 immunoreactivity was similar 
to that in the control group (p > 0.05) (Fig. 2). 
DLL-1 immunoreactivity
The immunoreactivity of DLL-1 was weak in livers 
of control mice (Fig. 1j) and control mice treated 
with sunitinib (Fig. 1k). In diabetic mice, DLL-1 
immunoreactivity was stronger in the liver (Fig. 1l) 
than in the control group (p < 0.05) (Fig. 2). Af-
ter sunitinib treatment of the diabetic mice the 
immunoreactivity of DLL-1 (Fig. 1i) significantly 
decreased. 
VEGF immunoreactivity
We observed significant differences in the hepatic 
VEGF expression between diabetic mice and dia-
betic mice treated with sunitinib (DM + S group) 
(p < 0.001) (Fig. 2). The hepatocytes of pericentral 
zone showed positive immunoreactivity for VEGF. 
The number of VEGF-positive cells in in the liver of 
diabetic mice (Fig. 1m) was higher than in diabetic 
mice treated with sunitinib (Fig. 1n). In livers of 
control mice treated with sunitinib (Fig. 1ö), VEGF 
immunoreactivity appeared similar to that of control 
mice (Fig. 1o and Fig. 2) (p > 0.05). 
Figure 2. Semiquantitative analysis of Notch1, Jagged1, DLL-1 and VEGF immunoreactivity in the livers of control (C), 
diabetic (DM), as sunitinib-treated control (C + S) and sunitinib-treated diabetic mice (DM + S). Statistical analyses 
showed strong statistically significant differences between diabetic mice and sunitinib-treated diabetic mice (p < 0.001). 
The differences between normal control (C) and sunitinib-treated normal mice (C + S) were statistically not significant 
(p > 0.05). The number of the immunoreactive cells per unit area was used to determine to intensity of the immunoreactivity. 
*p < 0.05, **p < 0.001, #p > 0.05 vs. control mice.
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Discussion
The effect of diabetes mellitus in various tissues is well 
recognized, but only limited data is known about the 
relationship between diabetic complications and liver 
function. There are different types of drugs used in 
the treatment of diabetes. To investigate the signaling 
pathways associated with diabetes it is important to 
ensure the development of new drugs. Therefore, in 
the present study we investigated the effect of STZ-in-
duced diabetes on mouse liver and tried to determine 
whether the tyrosine kinase inhibitor treatment pre-
vented the diabetes-induced liver injury.
Streptozotocin is derived from Streptomyces achro-
mogenes and is used as a diabetogenic agent for the 
induction of diabetes. STZ produces toxic radicals 
which destroy pancreatic b-cells and cause diabetes 
in experimental animals. However, the action mecha-
nism of STZ is not directed at pancreatic b-cells only, 
as other organs such as the liver, kidney and bone 
marrow are also affected by the STZ administration. 
Several studies reported that streptozotocin caused 
morphological biochemical, and pathological changes 
in many organs including the liver [21–24]. In this 
study, histological investigations showed hypertrophic 
hepatocytes with an increased amount of eosinophilic 
granules in STZ-treated mice. In the same group, the 
hepatocytes’ cytoplasm contained empty vacuole-like 
spaces. Similarly, Oršolić et al. found cellular vacuoli-
zation, cytoplasmic eosinophilia in the liver of diabetic 
mice [25]. The present study also showed the areas 
of fibrosis in the liver of mice belonging to the STZ 
group. Similar histopathological findings in the liver of 
diabetic rats were described by de Cavanagh et al. [26].
Sunitinib is a multitargeted receptor tyrosine 
kinase inhibitor that has potent antitumor and an-
tiangiogenic activities, and has been shown recently to 
be a novel therapeutic molecule for the treatment of 
diabetic patients [27]. Recently, there has been several 
publications related to the effects of sunitinib in T1D 
and T2D [11, 13, 16]. Agostino et al. reported that 
sunitinib significantly decreased the concentration 
of blood glucose in diabetic patients [16]. We found 
that the sunitinib treated diabetic mice, hypertrophy 
of hepatocytes, eosinophilic granules and the presence 
of fibrosis decreased. In result of all the morphological 
findings obtained from histopathological analysis, it 
was concluded that sunitinib has a protective effect 
against the hepatotoxicity produced by STZ diabetes.
Signal transduction pathways are important to 
understand the physiological and pathophysiological 
mechanisms of biological and pathological processes. 
The knowledge of the pathways involved in the path-
omechanisms of diabetes is necessary for the develop-
ment of new drugs for the management of diabetes. 
The Notch signaling pathway plays very important 
roles in many biological processes such as cell fate de-
cisions, cell proliferation, apoptosis, and cancer. Notch 
signaling pathway is involved in the regulation of liver 
metabolism since increased expression of Notch re-
ceptors and ligands was observed in liver injury [28]. 
Although Notch activation could contribute to liver 
regeneration and repair, sustained activation of Notch 
signaling is associated with liver diseases [28–30]. In 
the liver, Notch signaling has recently been recognized 
as a key player in glycogenolysis and gluconeogenesis 
processes [30]. Moreover, Notch may regulate hepatic 
vasculature, inflammation and liver fibrosis [29]. 
Valenti et al. reported that Notch regulates liver 
glucose and lipid homeostasis through forkhead box 
protein O1 (FoxO1), a transcription factor known to 
be the main target of insulin signaling [30]. We found 
that after sunitinib treatment of diabetic mice, the 
immunoexpression of Notch1, Jagged1 and DLL-1 
decreased significantly. At the same time, it affects 
immunoexpression of VEGF. The possible effect of 
sunitinib on VEGF immunoexpression may be due 
to targeting of VEGF receptors [31] or Notch-VEGF 
interactions [32]. Recently, the activation and upregu-
lation of Notch ligands and receptors in injured livers 
has been associated with liver fibrosis [29]. A previous 
study suggested that Jag-1 is highly expressed in in-
jured livers and stimulates alpha-smooth muscle actin 
and collagen production [33]. Notch inhibition by 
a g-secretase inhibitor reduced liver fibrosis [34]. 
When we used sunitinib in the treatment of diabetic 
mice, collagen deposits decreased significantly. Su-
nitinib may prevent liver fibrosis via inhibition of the 
Notch signaling pathway. Tuques et al. demonstrated 
that sunitinib has antifibrotic activity in liver [35], 
probably via targeting the PDGF and VEGF path-
ways [36].
Several signaling pathways play major roles in 
metabolic diseases, especially in receptor-targeted 
therapies. In-depth understanding of the cross-talk 
between signaling pathways may provide alternative 
solutions for the treatment of these diseases. Notch 
and RTKs act together to regulate cell fate. There is 
also some evidence that RTKs induce the expression 
of the Notch in particular by targeting Hes-1 [37]. 
Therefore, inhibitors targeting RTKs and signaling as-
sociated with RTKs could be therapeutically useful for 
the treatment of metabolic disorders such as diabetes.
Sunitinib is a small molecule tyrosine kinase in-
hibitor that is able to inhibit members of the RTK 
families containing vascular endothelial growth factor 
receptors (VEGFR), stem cell factor receptor (KIT), 
platelet-derived growth factor receptors (PDGFR) 
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[14, 15, 38]. Among the RTKs, VEGF receptors play 
a key role in vasculogenesis and angiogenesis [39, 40]. 
VEGF also regulates monocyte/macrophage migra-
tion and infiltration of tissues [41, 42]. Recent studies 
have demonstrated that VEGF signaling pathway may 
be associated with diabetes [43, 44]. The study by Cha 
et al. demonstrated that high glucose concentration 
increased VEGF expression in diabetic kidney [45]. 
Tsai et al. also reported that high glucose increases 
VEGF expression in human synovial fibroblasts via 
the ROS, PI3K, Akt, c-Jun and AP-1 signaling path-
way [46]. In the present study, we have shown that 
that VEGF immunoexpression was increased in the 
livers of STZ-induced diabetic mice, and that their 
treatment with sunitinib decreased VEGF immuno-
reactivity. VEGF expression in diabetic tissues may be 
associated with hypoxic conditions. Hypoxia induces 
the expression of VEGF by the transcription factor hy-
poxia-inducible factor-1a (HIF-1a). HIF-1a promotes 
new blood vessel formation through VEGF in some 
conditions [47]. Number of studies demonstrated that 
elevated glucose concentrations increased HIF-1a 
levels in diabetes [48, 49]. Haligur et al. showed that 
HIF-1a levels in hepatocytes increased in early stages 
of DM [50]. Enhanced expression of VEGF plays 
an important role in the pathogenesis of DM [42]. 
Our studies also confirm previous reports [48, 50] 
demonstrating increased levels of VEGF lead to de-
generative effects on liver. Therefore, blocking VEGF 
with sunitinib may represent an alternative treatment 
strategy for the treatment of T1D.
Our study showed that DM affects the structure 
of hepatocytes and liver tissue in STZ-induced di-
abetic mice. The results demonstrated that VEGF 
and Notch signaling pathway are associated with 
DM-related liver pathological changes. In addition, 
the study showed the beneficial effects of sunitinib in 
the prevention of diabetes-associated liver pathology 
occur via the reduced expression of Notch1, Jagged1, 
DLL-1 and VEGF. Further studies are necessary to 
check if sunitinib may be considered as an effective 
drug for the protection of liver in diabetes. 
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